Endo Aesthetics

Endo Aesthetics is a specialized business unit of Endo, Inc. (formerly Endo International) dedicated to the medical aesthetics market. The company's flagship product was Qwo (collagenase clostridium histolyticum-aaes), which made history as the first FDA-approved injectable treatment for moderate to severe cellulite in the buttocks of adult women. However, in December 2022, Endo announced it would cease the commercialization of Qwo due to concerns regarding the extent and duration of post-treatment bruising, which impacted market adoption. Despite the discontinuation of its primary product, the entity remains part of the broader Endo corporate structure, which recently emerged from financial restructuring in 2024. The company's focus has historically been on providing evidence-based aesthetic solutions through rigorous clinical development.